Erfaring har sommetider vist, at andre former af cysteamin tolereres dårligere (dvs. fører til flere bivirkninger) af patienter i dialyse.
Experience has occasionally shown that some forms of cysteamine are less well tolerated (i. e. leading to more adverse events) when patients are on dialysis.